JP2004016025A - Prophylactic agent for side effect of hardly digestible/absorbable sweet saccharide - Google Patents
Prophylactic agent for side effect of hardly digestible/absorbable sweet saccharide Download PDFInfo
- Publication number
- JP2004016025A JP2004016025A JP2002172182A JP2002172182A JP2004016025A JP 2004016025 A JP2004016025 A JP 2004016025A JP 2002172182 A JP2002172182 A JP 2002172182A JP 2002172182 A JP2002172182 A JP 2002172182A JP 2004016025 A JP2004016025 A JP 2004016025A
- Authority
- JP
- Japan
- Prior art keywords
- absorbable
- sweet
- side effects
- galactomannan
- digestible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、ガラクトマンナン分解物を難消化吸収性甘味糖質と共に摂取することにより、難消化吸収性甘味糖質の副作用を予防する予防剤に関する。
【0002】
【従来の技術】
現在、健康志向の増大から、シュガーレス・低カロリー商品のニーズが活発化しており、砂糖の代替品として、難消化吸収性甘味糖質が広く利用されている。
この難消化吸収性甘味糖質は消化吸収されない、または消化吸収されにくいことから、一定量以上まとめて摂取すると、腹部の膨満感、ゲップ、放屁、腹痛や急激な軟便化といった副作用を誘発するため、これらの糖質を利用した加工食品を設計、加工する場合に大きな問題となっている。
これまでに奥や小泉らにより難消化吸収性甘味糖質について素材ごとに最大無作用量が報告されており、商品設計する上で一つの基準となっている。例えば、ラクチトールで0.075g/体重kg、ソルビトールで0.15g/体重kg、ラクチュロースで0.26g/体重kg、マルチトールで0.30g/体重kgとなっている。体重50kgとすれば、ラクチトールで3.75g、ソルビトールで7.5g、ラクチュロースで13.0g、マルチトールで15.0gとなる。これらの量から、市場に多く出ている500mlのペットボトル飲料を作る場合を想定すると100ml当たりの量は、ラクチトールで0.75g、ソルビトールで1.5g、ラクチュロースで2.6g、マルチトールで6gとなり、非常に少ない量で副作用が誘発される可能性があることがわかる。今後、さらに難消化吸収性甘味糖質を含有したさまざまな食品が、開発され、それらを組み合わせて摂取する機会が増えることで、摂取量が最大無作用量を超え、副作用が誘発される危険性が非常に高くなると考えられるため、この副作用を予防する方法の必要性は非常に高いものである。
【0003】
難消化吸収性甘味糖質の副作用を予防する方法に関して、いくつかの報告がある。例えば、砂糖と難消化吸収性甘味糖質を混合し難消化吸収性甘味糖質の量を減らした方法(特開2001−72594)、素材ごとに最大無作用量を求め添加量を制限する方法(食品と開発,Vol.35,No2,p7−9,2000)や難消化吸収性甘味糖質の摂取方法を検討したもの(日本栄養・食糧学会誌,Vol.52,No.4,p201−208,1999)等がある。しかし、従来の方法では副作用予防効果が弱く、個人差もあるため、この問題を根本的に解決するに至っていない。即ち、従来にない難消化吸収性甘味糖質の副作用予防剤であり、かつ、各種飲食物に簡単に幅広く応用できる安全な難消化吸収性甘味糖質の副作用予防剤の開発が望まれていた。
【0004】
【発明が解決しようとする課題】
本発明は、ガラクトマンナン分解物を難消化吸収性甘味糖質と同時に摂取することにより、難消化吸収性甘味糖質の副作用を予防する予防剤に関する。
【0005】
【課題を解決するための手段】
本発明者らは、難消化吸収性甘味糖質が原因でおこる副作用を予防することを目的として鋭意研究を重ねた結果、ガラクトマンナン分解物が上記目的課題を解決することを見い出し、本発明を完成した。すなわち、本発明は、ガラクトマンナン分解物を含有することを特徴とする副作用の予防剤である。
【0006】
【実施の形態】
本発明に使用するガラクトマンナン分解物は、ガラクトマンナンを主成分とするグアーガム、ローカストビーンガム、タラガム、カシアガム、セスバニアガム等の天然粘質物、好ましくは、グアーガム、ローカストビーンガム、セスバニアガム、さらに好ましくはグアーガム、ローカストビーンガムを加水分解し低分子化することにより得られるものである。加水分解の方法としては、酵素分解法、酸分解法等、特に限定するものではないが、分解物の分子量が揃い易い点から酵素分解法が好ましい。酵素分解法に用いられる酵素は、マンノース直鎖を加水分解する酵素であれば市販のものでも天然由来のものでも特に限定されるものではないが、アスペルギルス属菌やリゾープス属菌等に由来するβ−マンナナーゼが好ましい。
【0007】
本発明に使用されるガラクトマンナン分解物は、2,000〜1,000,000の平均分子量を持つこと、及び0.5%水溶液の粘度がB型粘度計を用いて測定した時、25℃で50mPa・s以下であることが望ましい。好ましくは、30mPa・s以下、さらに好ましくは、10mPa・s以下である。平均分子量2,000以上であれば本発明の副作用改善効果を有するが、一方、平均分子量が1,000,000を超えると、粘度が高く食品に加工する場合に不都合が生じる場合が多いため、ガラクトマンナン分解物平均分子量は、2,000〜1,000,000である事が望ましい。特に好ましくは8,000〜100,000、さらに好ましくは、15,000〜25,000である。市販品としては、サンファイバー(太陽化学(株)製)、ファイバロン(大日本製薬(株)製)などが挙げられる。
【0008】
平均分子量の測定方法は、特に限定するものではないが、ポリエチレングリコール(分子量;2,000、20,000、100,000)をマーカーに高速液体クロマトグラフ法(カラム;YMC−Pack Diol−120(株)ワイエムシィ)を用いて、分子量分布を測定する方法等を用いることにより求めることができる。
当該副作用予防剤の各種飲食物への添加方法は、特に限定されるものではなく、あらかじめ原材料に添加したり、その製造工程中で添加したり、調理中に添加したり、喫食時に添加するなどが挙げられる。
【0009】
ガラクトマンナン分解物を有効成分とする副作用予防剤は、ガラクトマンナン分解物を含有すればその含有量については特に限定されるものではないが、そのままで使用したり、アミノ酸、ペプチド、デキストリン等の賦形剤を使用したり、形態は、液状、粉末等でも使用できる。
本発明の副作用予防剤の添加量は、特に限定されるものではないが、また添加量は対象とする難消化吸収性甘味糖質によって変動するが、難消化吸収性甘味糖質に対し予防効果が期待されるガラクトマンナン分解物の有効量は、難消化吸収性甘味糖質一部に対して1/1,000部以上、好ましくは1/100部以上、さらに好ましくは1部以上のガラクトマンナン分解物が確保し得る量が好ましい。
【0010】
本発品の副作用予防剤の併用物質としては、特に限定されるものではないが、アミノ酸、ペプチド、デキストリン、食物繊維などが挙げられ、好ましくは、デキストリン、アミノ酸、食物繊維、さらに好ましくは、デキストリン、食物繊維である。
難消化吸収性甘味糖質の副作用とは、難消化吸収性甘味糖質のような消化吸収されない、あるいは消化吸収されにくいものを、ある量以上まとめて摂取すると誘発される腹部の膨満感、ゲップ、放屁、腹痛や急激な軟便化といった副作用のことである。これらの特徴としては、その原因物質の摂取を中断すると改善されることである。
難消化吸収性甘味糖質とは、糖アルコール類、難消化性オリゴ糖類、難消化性デキストリン、ポリデキストロース等、難消化性の甘味をもつ糖質である。
【0011】
糖アルコール類とは、糖類の分子に水素を添加することにより、得られたアルコール基(−OH)をもつ糖質である。例えばソルビトール、還元水あめ、マルチトール、エリスリトール、還元パラチノース、ラクチトール、マンニトール、キシリトール等がある。好ましくは、ソルビトール、マルチトール、エリスリトール、還元パラチノース、ラクチトール、キシリトール、さらに好ましくは、ソルビトール、ラクチトールである。
難消化性オリゴ糖とは、構成糖が、分子2〜10鎖状から成る難消化性の糖質である。例えば、フラクトオリゴ糖、大豆オリゴ糖、ガラクトオリゴ糖、キシロオリゴ糖、乳果オリゴ糖、ラフィノース、ラクチュロース、パラチノースオリゴ糖、ニゲロオリゴ糖、ゲンチオリゴ糖等がある。好ましくは、フラクトオリゴ糖、大豆オリゴ糖、ガラクトオリゴ糖、キシロオリゴ糖、乳果オリゴ糖、さらに好ましくは、キシロオリゴ糖、乳果オリゴ糖である。
【0012】
本発明のガラクトマンナン分解物が、いかなる理由により、難消化吸収性甘味糖質の副作用誘発を予防するかについては、明確な作用メカニズムは解明されていないが、ガラクトマンナン分解物の有する粘度などの作用による糖質の胃から腸へのソフトリリースによる急激な腸内環境の変化の抑制(浸透圧等)、腸内で生産される短鎖脂肪酸による水の吸収性の増加や腸内絨毛の萎縮改善効果などが考えられる
以下、実施例を挙げて本発明をさらに詳細に説明するがこれにより限定されるものではない。
【0013】
【実施例】
実施例1
水900gに0.1N塩酸を加えてpH4.5に調整し、これにアスペルギルス属由来のβ−マンナナーゼ(阪急バイオインダストリー製)0.2gとグアーガム粉末(Lucid製)100gを添加混合して40〜45℃で24時間酵素を作用させた。反応後90℃、15分間加熱して酵素を失活させた。濾過分離(吸引濾過)して、不溶物を除去して得られた透明な溶液を減圧濃縮(エバポレーター;Yamato製)した後(固形分20%)、噴霧乾燥(大川原化工機(株))し、本発明品の飲食物の副作用予防剤であるガラクトマンナン分解物(平均分子量 約20,000)の粉末65gが得られた。このものの、0.5%水溶液をB型粘度計(東機産業(株))を用いて測定した時の粘度が2mPa・sであった。
【0014】
実施例2
水900gに0.1N塩酸を加えてpH3.0に調整し、これにアスペルギルス属由来のβ−マンナナーゼ(阪急バイオインダストリー製)0.15gとグアーガム粉末(Lucid製)100gを添加混合して40〜45℃で24時間酵素を作用させた。反応後90℃、15分間加熱して酵素を失活させた。濾過分離(吸引濾過)して、不溶物を除去して得られた透明な溶液を減圧濃縮(エバポレーター;Yamato製)した後(固形分20%)、噴霧乾燥(大川原化工機(株))し、本発明品の飲食物の副作用予防剤であるガラクトマンナン分解物(平均分子量約25,000)の粉末68gが得られた。このものの、0.5%水溶液をB型粘度計(東機産業(株))を用いて測定した時の粘度が3mPa・sであった。
【0015】
実施例3
水900gに0.1N塩酸を加えてpH4.0に調整した。これにバチルス属由来のβ−マンナナーゼ(阪急バイオインダストリー製)0.25gとグアーガム粉末(Lucid製)100gを添加混合して50〜55℃で12時間酵素を作用させた。反応後90℃、15分間加熱して酵素を失活させた。濾過分離(吸引濾過)して、不溶物を除去して得られた透明な溶液を減圧濃縮(エバポレーター;Yamato製)した後(固形分20%)、デキストリンを固形分の1/4量添加溶解し、噴霧乾燥(大川原化工機(株))し、本発明品の粉末80gが得られた。デキストリン添加前のガラクトマンナン分解物の平均分子量は、約15,000であり、このものの、0.5%水溶液をB型粘度計(東機産業(株))を用いて測定した時の粘度が9mPa・sであった。
【0016】
試験例1.
体重により無作為に割り付けした5週齢、体重70−90gのウイスター系雄性ラット30匹を3群(1群10匹)に分け表1に示すように、ソルビトール水溶液4g/kg体重を摂取させ副作用(腹部の膨張、急激な軟便化)を惹起した群、ソルビトール水溶液4g/kg体重とともに実施例1で得られたガラクトマンナン分解物を1.0もしくは、2.0g/kg体重で同時摂取した群について投与から5時間まで観察し、この効果を検討した。副作用発生率は、副作用が観察されたラットの匹数を一群の匹数で除し、100を乗じて求めた。
【0017】
【表1】
【0018】
表1より、明らかにガラクトマンナン分解物を同時摂取させることで副作用発生率が低下しており、副作用を予防することが確認された。
【0019】
試験例2.
Wistar系幼若雄ラット(3週齢、体重40−50g)40匹を4群(1群10匹)に分け、表2の処方で調製した飼料にて3日間飼育し、副作用(腹部の膨張、急激な軟便化)の発生率を検討した。
【0020】
【表2】
【0021】
【表3】
【0022】
表3より、明らかにガラクトマンナン分解物を同時摂取させることで副作用発生率が低下しており、副作用を予防することが確認された。
【0023】
試験例3
被験者(健康女性20名:平均年齢20歳、平均体重57kg)に、試験食I:ラクチトール15g、試験食II:ガラクトマンナン分解物(実施例1)5g+ラクチトール15g、試験食III:ガラクトマンナン分解物(実施例2)5g+ラクチトール15g、試験食IV:ガラクトマンナン分解物(実施例3)6.5g+ラクチトール15gを摂取させ副作用発生率(腹部の膨満感、ゲップ、放屁、腹痛や急激な軟便化)について検討を行った。ここで副作用発生率は、副作用を訴えた被験者の人数を被験者参加人数で除し、100を乗じて求めた。
【0024】
【表4】
【0025】
表4より、明らかにガラクトマンナン分解物を同時摂取させることで副作用発生率が低下しており、副作用を予防することが確認された
【0026】
【発明の効果】
本発明品である難消化吸収性甘味糖質の副作用予防剤は、簡単に飲食物に応用することが可能であり、さらに、副作用を予防することで難消化吸収性甘味糖質を使用した食品の安全性を高める効果を提供することが可能である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a prophylactic agent which prevents side effects of an indigestible and absorbable sweet saccharide by ingesting a degraded galactomannan together with the indigestible and absorbable sweet saccharide.
[0002]
[Prior art]
At present, the need for sugarless and low-calorie products is increasing due to an increase in health consciousness, and indigestible and absorbable sweet saccharides are widely used as sugar substitutes.
Since this hardly digestible and absorbable sweet saccharide is not digested or absorbed or is hardly digested and absorbed, ingesting a certain amount or more collectively may cause side effects such as abdominal bloating, burp, flatus, abdominal pain and sudden loosening of stool. This is a major problem when designing and processing processed foods using these sugars.
So far, Oku and Koizumi have reported the maximum no-effect level for each of the indigestible and absorbable sweet saccharides, which is one criterion for product design. For example, the weight is 0.075 g / kg for lactitol, 0.15 g / kg for sorbitol, 0.26 g / kg for lactulose, and 0.30 g / kg for maltitol. Assuming a body weight of 50 kg, the weight is 3.75 g for lactitol, 7.5 g for sorbitol, 13.0 g for lactulose, and 15.0 g for maltitol. From these amounts, assuming that 500 ml of PET bottle drinks that are widely available on the market are made, the amount per 100 ml is 0.75 g for lactitol, 1.5 g for sorbitol, 2.6 g for lactulose, and 6 g for maltitol. Which indicates that a very small amount may induce side effects. In the future, a variety of foods containing indigestible and absorbable sweet saccharides will be developed and the chances of combining them will increase, so that the intake will exceed the maximum no-effect level and the risk of inducing side effects Therefore, the need for a method to prevent this side effect is very high.
[0003]
There are several reports on how to prevent the side effects of indigestible and sweet sugars. For example, a method of mixing sugar and an indigestible and absorbable sweet saccharide to reduce the amount of the indigestible and absorbable sweet saccharide (JP-A-2001-72594), a method of obtaining the maximum non-active amount for each material and limiting the amount added (Food and Development, Vol. 35, No. 2, p7-9, 2000) and the method of ingesting indigestible and absorbable sweet saccharides (Japanese Journal of Nutrition and Food Science, Vol. 52, No. 4, p201-). 208, 1999). However, the conventional method has a weak effect of preventing side effects and individual differences, so that this problem has not been fundamentally solved. That is, it has been desired to develop a safe side effect preventive agent for hardly digestible and absorptive sweet saccharides that is an unprecedented side effect preventive agent for hardly digestible and absorptive sweet saccharides and that can be easily and widely applied to various foods and drinks. .
[0004]
[Problems to be solved by the invention]
TECHNICAL FIELD The present invention relates to a prophylactic agent which prevents side effects of a hardly digestible and absorbable sweet saccharide by ingesting a degraded galactomannan simultaneously with the poorly digestible and absorbable sweet saccharide.
[0005]
[Means for Solving the Problems]
The present inventors have conducted intensive studies with the aim of preventing side effects caused by indigestible and absorbable sweet saccharides, and as a result, have found that a galactomannan hydrolyzate can solve the above-mentioned object, and have achieved the present invention. completed. That is, the present invention is a preventive agent for side effects, comprising a galactomannan hydrolyzate.
[0006]
Embodiment
Galactomannan degradation products used in the present invention, guar gum containing galactomannan as a main component, locust bean gum, tara gum, cassia gum, natural mucilage such as sesbania gum, preferably, guar gum, locust bean gum, sesbania gum, more preferably Is obtained by hydrolyzing guar gum and locust bean gum to reduce the molecular weight. The method of hydrolysis is not particularly limited, such as an enzymatic decomposition method and an acid decomposition method, but the enzymatic decomposition method is preferable because the molecular weights of the decomposition products are easily uniform. The enzyme used in the enzymatic degradation method is not particularly limited as long as it is a commercially available enzyme or an enzyme of natural origin as long as it is an enzyme that hydrolyzes a mannose linear chain, but β-derived from Aspergillus, Rhizopus, etc. -Mannanase is preferred.
[0007]
The degraded galactomannan used in the present invention has an average molecular weight of 2,000 to 1,000,000, and the viscosity of a 0.5% aqueous solution is 25 ° C. when measured using a B-type viscometer. Is preferably 50 mPa · s or less. It is preferably at most 30 mPa · s, more preferably at most 10 mPa · s. When the average molecular weight is 2,000 or more, the side effect improving effect of the present invention is obtained. On the other hand, when the average molecular weight exceeds 1,000,000, inconveniences often occur when processed into foods having high viscosity, The average molecular weight of the decomposed product of galactomannan is desirably 2,000 to 1,000,000. Especially preferably, it is 8,000-100,000, More preferably, it is 15,000-25,000. Commercially available products include Sunfiber (manufactured by Taiyo Kagaku Co., Ltd.) and Fiberron (manufactured by Dainippon Pharmaceutical Co., Ltd.).
[0008]
The method for measuring the average molecular weight is not particularly limited, but high-performance liquid chromatography (column; YMC-Pack Diol-120 (column: YMC-Pack Diol-120) using polyethylene glycol (molecular weight; 2,000, 20,000, 100,000) as a marker. (Y.M.C.) and a method of measuring the molecular weight distribution.
The method of adding the side effect preventive agent to various foods and drinks is not particularly limited, and may be added to raw materials in advance, added during the manufacturing process, added during cooking, added at the time of eating, etc. Is mentioned.
[0009]
The side effect preventive agent containing a galactomannan hydrolyzate as an active ingredient is not particularly limited in its content as long as it contains the galactomannan hydrolyzate, but it can be used as it is, or can be used as an amino acid, peptide, dextrin, etc. A shaping agent may be used, and a form such as liquid or powder may be used.
The addition amount of the side effect preventive agent of the present invention is not particularly limited, and the addition amount varies depending on the target indigestible and absorbable sweet saccharide, but the preventive effect on the indigestible and absorbable sweet saccharide is preferred. The effective amount of the degraded galactomannan is expected to be at least 1 / 1,000 parts, preferably at least 1/100 parts, more preferably at least 1 part of the indigestible and absorbable sweet saccharide. The amount that the decomposition product can secure is preferable.
[0010]
Examples of the concomitant substance of the side effect preventive agent of the present product include, but are not particularly limited to, amino acids, peptides, dextrins, dietary fiber, and the like, preferably dextrins, amino acids, dietary fiber, and more preferably dextrin. , Is a dietary fiber.
The side effects of indigestible and absorbable sweet saccharides include abdominal bloating and gulp induced by taking a certain amount of indigestible or indigestible such as indigestible and absorbable sweet saccharides. Side effects such as flatus, abdominal pain and sudden loosening of stool. These characteristics are improved when the intake of the causative substance is stopped.
The hardly digestible and absorbable sweet saccharides are sugars having indigestible sweetness such as sugar alcohols, hardly digestible oligosaccharides, hardly digestible dextrins, and polydextrose.
[0011]
Sugar alcohols are saccharides having an alcohol group (-OH) obtained by adding hydrogen to saccharide molecules. Examples include sorbitol, reduced starch syrup, maltitol, erythritol, reduced palatinose, lactitol, mannitol, xylitol and the like. Preferably, sorbitol, maltitol, erythritol, reduced palatinose, lactitol, xylitol, more preferably sorbitol, lactitol.
The indigestible oligosaccharide is an indigestible saccharide in which the constituent sugars are composed of 2 to 10 chains of molecules. For example, fructooligosaccharides, soybean oligosaccharides, galactooligosaccharides, xylo-oligosaccharides, nectar oligosaccharides, raffinose, lactulose, palatinose oligosaccharides, nigerooligosaccharides, gentioligosaccharides, and the like. Preferably, it is a fructooligosaccharide, a soybean oligosaccharide, a galactooligosaccharide, a xylo-oligosaccharide, a milk oligosaccharide, more preferably, a xylo-oligosaccharide or a milk oligosaccharide.
[0012]
Regarding the reason why the galactomannan hydrolyzate of the present invention prevents the induction of side effects of the indigestible and absorbable sweet saccharide, a clear mechanism of action has not been elucidated. Suppresses rapid changes in the intestinal environment by the soft release of carbohydrates from the stomach to the intestine (eg, osmotic pressure), increases water absorption by short-chain fatty acids produced in the intestine, and atrophy the intestinal villi Hereinafter, the present invention will be described in more detail with reference to Examples, which are not intended to limit the present invention.
[0013]
【Example】
Example 1
To 900 g of water, 0.1N hydrochloric acid was added to adjust the pH to 4.5, and 0.2 g of Aspergillus-derived β-mannanase (manufactured by Hankyu Bioindustry) and 100 g of guar gum powder (manufactured by Lucid) were added and mixed. The enzyme was allowed to act at 45 ° C. for 24 hours. After the reaction, the mixture was heated at 90 ° C. for 15 minutes to inactivate the enzyme. The transparent solution obtained by filtering and separating (suction filtration) to remove insolubles was concentrated under reduced pressure (evaporator; manufactured by Yamato) (solid content: 20%), and spray-dried (Okawara Kakoki Co., Ltd.). As a result, 65 g of powder of a degraded product of galactomannan (average molecular weight: about 20,000), which is an agent for preventing side effects of food and drink of the present invention, was obtained. However, when the 0.5% aqueous solution was measured using a B-type viscometer (Toki Sangyo Co., Ltd.), the viscosity was 2 mPa · s.
[0014]
Example 2
To 900 g of water, 0.1N hydrochloric acid was added to adjust the pH to 3.0, and 0.15 g of Aspergillus-derived β-mannanase (manufactured by Hankyu Bioindustry) and 100 g of guar gum powder (manufactured by Lucid) were added and mixed. The enzyme was allowed to act at 45 ° C. for 24 hours. After the reaction, the mixture was heated at 90 ° C. for 15 minutes to inactivate the enzyme. The transparent solution obtained by filtering and separating (suction filtration) to remove insolubles was concentrated under reduced pressure (evaporator; manufactured by Yamato) (solid content: 20%), and spray-dried (Okawara Kakoki Co., Ltd.). As a result, 68 g of a powder of galactomannan hydrolyzate (average molecular weight: about 25,000), which is an agent for preventing side effects of food and drink of the product of the present invention, was obtained. However, when the 0.5% aqueous solution was measured using a B-type viscometer (Toki Sangyo Co., Ltd.), the viscosity was 3 mPa · s.
[0015]
Example 3
0.1N hydrochloric acid was added to 900 g of water to adjust the pH to 4.0. To this, 0.25 g of Bacillus-derived β-mannanase (manufactured by Hankyu Bioindustry) and 100 g of guar gum powder (manufactured by Lucid) were added and mixed, and the enzyme was allowed to act at 50 to 55 ° C. for 12 hours. After the reaction, the mixture was heated at 90 ° C. for 15 minutes to inactivate the enzyme. After filtration separation (suction filtration) to remove insolubles, the resulting clear solution was concentrated under reduced pressure (evaporator; manufactured by Yamato) (solid content: 20%), and dextrin was added and dissolved by 1/4 of the solid content. Then, it was spray-dried (Okawara Kakoki Co., Ltd.) to obtain 80 g of the powder of the present invention. The average molecular weight of the galactomannan hydrolyzate before the addition of dextrin is about 15,000, and when the 0.5% aqueous solution is measured using a B-type viscometer (Toki Sangyo Co., Ltd.), It was 9 mPa · s.
[0016]
Test Example 1
As shown in Table 1, 30 male Wistar male rats weighing 70-90 g and weighing 70-90 g were randomly assigned according to body weight, and as shown in Table 1, 4 g / kg body weight of sorbitol aqueous solution was ingested. (Abdominal swelling, rapid loosening of feces), group in which galactomannan hydrolyzate obtained in Example 1 was simultaneously taken at 1.0 or 2.0 g / kg body weight together with 4 g / kg body weight of sorbitol aqueous solution. Was observed up to 5 hours after administration to examine this effect. The incidence of side effects was determined by dividing the number of rats in which side effects were observed by the number of rats in one group and multiplying by 100.
[0017]
[Table 1]
[0018]
From Table 1, it was confirmed that the incidence of side effects was clearly reduced by simultaneous ingestion of the degraded galactomannan, and that side effects were prevented.
[0019]
Test Example 2.
Forty Wistar juvenile male rats (3 weeks old, weighing 40-50 g) were divided into 4 groups (10 rats per group) and reared for 3 days on a feed prepared according to the formulation shown in Table 2, and side effects (abdominal swelling) were observed. , And sudden loosening of feces) were examined.
[0020]
[Table 2]
[0021]
[Table 3]
[0022]
From Table 3, it was confirmed that the concurrent incidence of the galactomannan degradation product reduced the incidence of side effects and prevented the side effects.
[0023]
Test example 3
To test subjects (20 healthy women: average age 20 years, average weight 57 kg), test meal I: lactitol 15 g, test meal II: galactomannan hydrolyzate (Example 1) 5 g + lactitol 15 g, test meal III: galactomannan hydrolyzate (Example 2) 5 g + lactitol 15 g, test meal IV: Galactomannan hydrolyzate (Example 3) 6.5 g + lactitol 15 g was ingested to cause side effects (abdominal swelling, burp, flatus, abdominal pain and sudden loosening of stool) Was examined. Here, the incidence of side effects was determined by dividing the number of subjects complaining of side effects by the number of participants and multiplying by 100.
[0024]
[Table 4]
[0025]
From Table 4, it was confirmed that the concurrent intake of the degraded galactomannan reduced the incidence of side effects and prevented the side effects.
【The invention's effect】
The agent for preventing side effects of the hardly digestible and absorbable sweet saccharide which is the product of the present invention can be easily applied to foods and drinks, and further, the food using the hardly digestible and absorbable sweet saccharide by preventing side effects. It is possible to provide an effect of increasing the safety of the vehicle.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002172182A JP4083473B2 (en) | 2002-06-13 | 2002-06-13 | Anti-digestible sweet saccharide side effect preventive agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002172182A JP4083473B2 (en) | 2002-06-13 | 2002-06-13 | Anti-digestible sweet saccharide side effect preventive agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004016025A true JP2004016025A (en) | 2004-01-22 |
JP4083473B2 JP4083473B2 (en) | 2008-04-30 |
Family
ID=31171811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002172182A Expired - Fee Related JP4083473B2 (en) | 2002-06-13 | 2002-06-13 | Anti-digestible sweet saccharide side effect preventive agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4083473B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007022992A (en) * | 2005-07-20 | 2007-02-01 | Taiyo Kagaku Co Ltd | Preparation for hyperphosphatemia, and food, drink or feed containing the same |
JP2013066476A (en) * | 2006-01-25 | 2013-04-18 | Tate & Lyle Ingredients Americas Llc | Food product comprising slowly digestible or digestion resistant carbohydrate composition |
US9868969B2 (en) | 2006-01-25 | 2018-01-16 | Tate & Lyle Ingredients Americas Llc | Fiber-containing carbohydrate composition |
US11540549B2 (en) | 2019-11-28 | 2023-01-03 | Tate & Lyle Solutions Usa Llc | High-fiber, low-sugar soluble dietary fibers, products including them and methods for using them |
-
2002
- 2002-06-13 JP JP2002172182A patent/JP4083473B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007022992A (en) * | 2005-07-20 | 2007-02-01 | Taiyo Kagaku Co Ltd | Preparation for hyperphosphatemia, and food, drink or feed containing the same |
JP2013066476A (en) * | 2006-01-25 | 2013-04-18 | Tate & Lyle Ingredients Americas Llc | Food product comprising slowly digestible or digestion resistant carbohydrate composition |
US9868969B2 (en) | 2006-01-25 | 2018-01-16 | Tate & Lyle Ingredients Americas Llc | Fiber-containing carbohydrate composition |
US9957537B2 (en) | 2006-01-25 | 2018-05-01 | Tate & Lyle Ingredients Americas Llc | Fiber-containing carbohydrate composition |
US9963726B2 (en) | 2006-01-25 | 2018-05-08 | Tate & Lyle Ingredients Americas Llc | Fiber-containing carbohydrate composition |
US10344308B2 (en) | 2006-01-25 | 2019-07-09 | Tate & Lyle Ingredients Americas Llc | Fiber-containing carbohydrate composition |
US11540549B2 (en) | 2019-11-28 | 2023-01-03 | Tate & Lyle Solutions Usa Llc | High-fiber, low-sugar soluble dietary fibers, products including them and methods for using them |
Also Published As
Publication number | Publication date |
---|---|
JP4083473B2 (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5702042B2 (en) | Concentrated liquid preparation | |
ES2258076T3 (en) | INULIN PRODUCTS WITH IMPROVED NUTRITIONAL PROPERTIES. | |
CN102458151B (en) | Liquid enteral nutritional composition with a low monovalent metal ion content | |
JP4793533B2 (en) | Stimulation of the immune system with polydextrose | |
AU2006340316B2 (en) | High-calorie nutritional supplement | |
JP4242589B2 (en) | Improved protein-containing infant formula | |
JP4626752B2 (en) | Novel uses of carbohydrates and compositions | |
CN102264246A (en) | Liquid high-fat protein composition | |
KR20150015030A (en) | Novel sweetener having sucrose-like taste, method for producing the same, and use of the same | |
UA73763C2 (en) | Carbohydrate composition containing prebiotic for treatment or prevention of measles | |
CA2174602A1 (en) | .alpha.-glucosidase inhibitor, composition principally comprising sugar and containing the same, sweetener, food and feed | |
CN101043900A (en) | Peptide mixture | |
JP2009167646A (en) | Liver function protective agent | |
WO2006104137A1 (en) | Sucrase activity inhibitor, glucoamylase activity inhibitor and food and feed containing the same | |
JP4034024B2 (en) | Functional food | |
JP4083473B2 (en) | Anti-digestible sweet saccharide side effect preventive agent | |
CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
JPWO2005056022A1 (en) | Composition for improving bowel disease | |
KR20170109380A (en) | manufacturing method of sweet jelly containing mealworm and sweet jelly containing mealworm made by the same | |
JP4634757B2 (en) | Emulsified liquid enteral nutrient | |
JP2010059105A (en) | Preventing or treating agent for inflammatory bowel disease | |
JP4105615B2 (en) | Milk beverage, osteoarthritis ameliorating agent, and method for producing milk beverage | |
CN108685101A (en) | Wood frog peptide inulin | |
JP5371415B2 (en) | Bone density reduction inhibiting composition | |
CN108783415A (en) | Wood frog peptide zaocys dhumnade seabuckthorn fruit powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050608 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4083473 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120222 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120222 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130222 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140222 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |